Combination vaccines are a cost-effective approach to safeguarding livestock health and ensuring efficient disease management.
Together with partners, GALVmed has supported the development of combination vaccines against several ruminant diseases.
New combination vaccine against CCPP, SGP, and PPR to be administered for the first time in Kenya on World Veterinary Day
A novel combination vaccine has been launched in Kenya to help protect sheep and goat herds against three of the most common and devastating diseases: Contagious Caprine Pleuropneumonia (CCPP), Sheep and Goat Pox (SGP), and Peste des Petits Ruminants (PPR).
The new vaccine was unveiled at the 60th Kenya Veterinary Association Congress on April 22 and it will be administered for the first time in Kenya at a farm in Kwale county on World Veterinary Day, April 25.
We’re excited to share GALVmed’s 2025 Year in Review, an overview of our accomplishments and the progress made throughout the year in advancing our mission.
The review reflects a year of meaningful impact and our continued commitment to strengthening livelihoods through improved livestock health.
Read it here.
Transformational improvement in the well-being and economic progression of small-scale livestock producers.
We will contribute to the transformation of small-scale livestock producers’ lives by:
Product development
GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.
Commercial development
Our work with our partners supports the small-scale livestock producers of the world.
Enabling environment
An enabling environment that allows for the successful translation of research products to sustainable animal health solutions for small scale livestock producers is essential to achieving GALVmed’s mission.
The candidate vaccine is a novel target identified on the surface of haemorrhagic septicaemia-associated strains of Pasteurella multocida. It has demonstrated robust protection in cattle against lethal challenge with the two serogroups of Pasteurella responsible for HS.
Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.
Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.
The candidate vaccine is a novel target identified on the surface of haemorrhagic septicaemia-associated strains of Pasteurella multocida. It has demonstrated robust protection in cattle against lethal challenge with the two serogroups of Pasteurella responsible for HS.
Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.
Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.
If Africa can mobilise the investments needed to eliminate sleeping sickness in people, it can and must show the same commitment to protecting the animals that sustain its economy.
Imagine that over the course of 10 days, 80 per cent of your livelihood is destroyed. This is a reality for millions of small-scale producers in Africa who depend on sheep and goats for income, nutrition and survival, but have to contend with Peste des Petits Ruminants (PPR), a highly contagious disease with a mortality rate of up to 90 per cent.